INHIBACE

This brand name is authorized in Austria, Canada, Poland, Turkey, South Africa

Active ingredients

The drug INHIBACE contains one active pharmaceutical ingredient (API):

1 Cilazapril UNII 19KW7PI29F - CILAZAPRIL

Cilazapril is a specific, long-acting angiotensin-converting enzyme (ACE) inhibitor which suppresses the renin-angiotensin-aldosterone system and thereby the conversion of the inactive angiotensin I to angiotensin II, which is a potent vasoconstrictor. Read about Cilazapril

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
INHIBACE Tablet	Health Products and Food Branch (CA)	MPI, CA: SPM

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
C09AA08	Cilazapril	C Cardiovascular system → C09 Agents acting on the renin-angiotensin system → C09A ACE inhibitors, plain → C09AA ACE inhibitors, plain
Discover more medicines within C09AA08

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: CA	Health Products and Food Branch	Identifier(s): 01911473, 01911481
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100030624, 100030630, 100042521, 100057391, 100246904, 100259284, 100265304, 100283578, 100294056, 100326098, 100334293, 100334301, 100342200, 100343620, 100344191, 100360617, 100360623, 100398057, 100435338
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8699511099003, 8699511099010, 8699511099027
Country: ZA	Health Products Regulatory Authority	Identifier(s): Y/7.1.3/66